Literature DB >> 1375134

Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.

J Laliberté1, V E Marquez, R L Momparler.   

Abstract

Deamination of the nucleoside analogues ARA-C and 5-AZA-CdR by CR deaminase results in a loss of antileukemic activity. To prevent the inactivation of these analogues, inhibitors of CR deaminase may prove to be useful agents. In the present study we investigated the effects of the deaminase inhibitors Zebularine, 5-F-Zebularine, and diazepinone riboside on the deamination of CR, ARA-C, and 5-AZA-CdR using highly purified human CR deaminase (EC 3.5.4.5). These inhibitors produced a competitive type of inhibition with each substrate, the potency of which followed the patterns diazepinone riboside greater than 5-F-Zebularine and THU greater than Zebularine. 5-AZA-CdR was more sensitive than ARA-C to the inhibition produced by these deaminase inhibitors. The inhibition constants for diazepinone riboside lay in the range of 5-15 nM, suggesting that this inhibitor could be an excellent candidate for use in combination chemotherapy with either ARA-C or 5-AZA-CdR in patients with leukemia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375134     DOI: 10.1007/bf00686478

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  27 in total

1.  In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2'-deoxycytidine.

Authors:  N Onetto; R L Momparler; L F Momparler; M Gyger
Journal:  Semin Oncol       Date:  1987-06       Impact factor: 4.929

2.  Inhibition of cytidine deaminase by 2-oxopyrimidine riboside and related compounds.

Authors:  J J McCormack; V E Marquez; P S Liu; D T Vistica; J S Driscoll
Journal:  Biochem Pharmacol       Date:  1980-03-01       Impact factor: 5.858

3.  Purification and properties of cytidine deaminase from normal and leukemic granulocytes.

Authors:  B A Chabner; D G Johns; C N Coleman; J C Drake; W H Evans
Journal:  J Clin Invest       Date:  1974-03       Impact factor: 14.808

4.  Cytidine deaminase and the development of resistance to arabinosyl cytosine.

Authors:  C D Steuart; P J Burke
Journal:  Nat New Biol       Date:  1971-09-22

5.  Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside.

Authors:  G G Chabot; J Bouchard; R L Momparler
Journal:  Biochem Pharmacol       Date:  1983-04-01       Impact factor: 5.858

6.  Metabolism of 1-beta-D-arabinofuranosyluracil in mouse L5178Y cells.

Authors:  W E Müller; R K Zahn
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

7.  Synthesis of 1,3-diazepin-2-one nucleosides as transition-state inhibitors of cytidine deaminase.

Authors:  V E Marquez; P S Liu; J A Kelley; J S Driscoll; J J McCormack
Journal:  J Med Chem       Date:  1980-07       Impact factor: 7.446

8.  On the interaction of 3,4,5,6-tetrahydrouridine with human liver cytidine deaminase.

Authors:  D F Wentworth; R Wolfenden
Journal:  Biochemistry       Date:  1975-11-18       Impact factor: 3.162

9.  Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine.

Authors:  R L Momparler; J Laliberté
Journal:  Leuk Res       Date:  1990       Impact factor: 3.156

10.  Improved prospects for long-term survival in adults with acute myelogenous leukemia.

Authors:  M J Keating; K B McCredie; G P Bodey; T L Smith; E Gehan; E J Freireich
Journal:  JAMA       Date:  1982-11-19       Impact factor: 56.272

View more
  19 in total

1.  Relatively small increases in the steady-state levels of nucleobase deamination products in DNA from human TK6 cells exposed to toxic levels of nitric oxide.

Authors:  Min Dong; Peter C Dedon
Journal:  Chem Res Toxicol       Date:  2006-01       Impact factor: 3.739

Review 2.  The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?

Authors:  Audrey Frances; Pierre Cordelier
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

3.  Creation of zebularine-resistant human cytidine deaminase mutants to enhance the chemoprotection of hematopoietic stem cells.

Authors:  Hongmei Ruan; Songbo Qiu; Brian C Beard; Margaret E Black
Journal:  Protein Eng Des Sel       Date:  2016-05-08       Impact factor: 1.650

4.  Contrasting behavior of conformationally locked carbocyclic nucleosides of adenosine and cytidine as substrates for deaminases.

Authors:  Victor E Marquez; Gottfried K Schroeder; Olaf R Ludek; Maqbool A Siddiqui; Abdallah Ezzitouni; Richard Wolfenden
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2009-05       Impact factor: 1.381

5.  DNA Methylation Inhibitor Zebularine Confers Stroke Protection in Ischemic Rats.

Authors:  Hua Dock; Annette Theodorsson; Elvar Theodorsson
Journal:  Transl Stroke Res       Date:  2015-04-01       Impact factor: 6.829

6.  Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.

Authors:  D H Horber; H Schott; R A Schwendener
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells.

Authors:  Jonathan C Cheng; Daniel J Weisenberger; Felicidad A Gonzales; Gangning Liang; Guo-Liang Xu; Ye-Guang Hu; Victor E Marquez; Peter A Jones
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

8.  Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.

Authors:  Madhavi Billam; Michele D Sobolewski; Nancy E Davidson
Journal:  Breast Cancer Res Treat       Date:  2009-05-21       Impact factor: 4.872

9.  Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.

Authors:  Jan H Beumer; Julie L Eiseman; Robert A Parise; Jeffry A Florian; Erin Joseph; David Z D'Argenio; Robert S Parker; Brittany Kay; Joseph M Covey; Merrill J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  2007-11-15       Impact factor: 3.333

10.  Synthesis and conformational analysis of locked carbocyclic analogues of 1,3-diazepinone riboside, a high-affinity cytidine deaminase inhibitor.

Authors:  Olaf R Ludek; Gottfried K Schroeder; Chenzhong Liao; Pamela L Russ; Richard Wolfenden; Victor E Marquez
Journal:  J Org Chem       Date:  2009-08-21       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.